U.S. flag

An official website of the United States government

GTR Home > Conditions/Phenotypes > Tumor predisposition syndrome 2

Summary

Tumor predisposition syndrome-2 (TPDS2) is an autosomal recessive cancer predisposition syndrome characterized by the onset of various types of tumors or malignancies in young adulthood. The most common clinical manifestations include acute myeloid leukemia (AML), myelodysplastic syndrome, colorectal adenomatous polyposis and carcinoma, and uveal melanoma, although other tumors and malignancies have been reported (summary by Palles et al., 2022). For a discussion of genetic heterogeneity of TPDS, see TPDS1 (614327). [from OMIM]

Available tests

1 test is in the database for this condition.

Genes See tests for all associated and related genes

  • Also known as: MED1, TPDS2, UVM1, MBD4
    Summary: methyl-CpG binding domain 4, DNA glycosylase

Clinical features

Help

Show allHide all

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.